Key Highlights
- Net loss was USD 48.1 million for the third quarter ended September 30, 2026, against USD 48.2 million a year earlier, or USD 7.36 per share versus USD 16.92 after a 1-for-80 reverse split.
- Revenue rose to USD 38.4 million from USD 13.3 million, mainly because the termination of the Chiesi agreement released USD 37.1 million of contract liabilities into revenue.
- Other expense, net was USD 55.3 million, including a USD 96.2 million loss on issuing warrants in the August 2026 private placement, partly offset by a USD 39.7 million gain on Warrant fair value.
- Cash, cash equivalents and marketable securities were USD 51.2 million, and management believes Working Capital can fund operations into the first quarter of 2027, with Going Concern doubt disclosed.
Chiesi Exit Lifts Revenue but Warrant Charges Hold the Loss
Gossamer Bio (NASDAQ:GOSS) filed its Quarterly Report on November 10, 2026. Revenue of USD 38.4 million compared with USD 13.3 million, a one-off lift because the Chiesi collaboration ended in July 2026, and the company said it will recognize no further revenue under that agreement. Research and Development expense fell to USD 18.8 million from USD 45.5 million as seralutinib trial costs dropped by USD 27.3 million, while general and administrative expense edged up to USD 9.6 million from USD 9.4 million. The net loss still held near USD 48 million because other expense, net swung to USD 55.3 million from income of USD 0.9 million a year earlier.
Seralutinib NDA and the Chiesi Rights Reacquisition
The company is a clinical-stage biopharmaceutical Business developing seralutinib for pulmonary hypertension, including pulmonary arterial hypertension and PH-ILD. On July 23, 2026 it agreed with Chiesi to reacquire worldwide development and commercial rights. The Phase 3 PROSERA study in February 2026 showed a placebo-adjusted improvement of 13.3 meters in the six-minute walk distance at Week 24, with a p-value of 0.0320 that missed the prespecified threshold of 0.025. After a mid-June FDA meeting, Gossamer Bio (NASDAQ:GOSS) submitted its new drug application in September 2026. If the FDA accepts it for filing, the filing says an approval decision could come in the third quarter of 2027.
Contingent USD 125 Million Second Closing and Going Concern Doubt
On August 24, 2026 the company closed the first part of a private Placement for about USD 25.0 million of gross proceeds, or about USD 22.8 million after costs. A second closing of about USD 125.0 million depends on the FDA accepting the application for filing in 2026 and ends if it has not occurred by December 31, 2026. Milestone-based warrants issued then could add about USD 100.0 million if exercised in full after approval. Separately, holders tendered 90.5% of the 2027 notes in an exchange, and the nine-month results include a USD 43.8 million gain on Debt extinguishment. A 1-for-80 reverse split on September 10, 2026 restored Nasdaq compliance. Its filing states its cash is not sufficient for one year, which raises substantial doubt about continuing as a going concern.
Where Things Stand
Largely through non-operating items. Gossamer Bio (NASDAQ:GOSS) cut research spending sharply and booked USD 38.4 million of revenue as the Chiesi agreement ended, yet USD 55.3 million of other expense, driven by a USD 96.2 million warrant issuance loss, kept the loss near USD 48 million. Nine-month net loss narrowed to USD 77.8 million from USD 123.1 million, helped by the debt extinguishment gain. The next markers are the FDA decision on accepting the application for filing, the second closing before December 31, 2026, and the cash runway into early 2027.






Please wait processing your request...